Fidelis Capital Partners LLC Acquires Shares of 364 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fidelis Capital Partners LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 364 shares of the biopharmaceutical company’s stock, valued at approximately $320,000.

Other large investors have also recently added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Sunbelt Securities Inc. acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $25,000. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $31,000. Bruce G. Allen Investments LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $40,000. Finally, Sutton Wealth Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.3 %

Regeneron Pharmaceuticals stock opened at $896.82 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm has a market capitalization of $98.43 billion, a price-to-earnings ratio of 25.81, a PEG ratio of 2.58 and a beta of 0.11. The company’s 50 day simple moving average is $953.01 and its 200 day simple moving average is $891.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business’s quarterly revenue was up .6% on a year-over-year basis. During the same period last year, the company posted $10.96 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.59 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,707 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the sale, the director now directly owns 6,382 shares in the company, valued at approximately $6,062,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph L. Goldstein sold 2,707 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the sale, the director now owns 6,382 shares in the company, valued at $6,062,900. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,729 shares of company stock worth $13,124,641. Company insiders own 8.83% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of several recent research reports. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. UBS Group boosted their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Finally, Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $976.41.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.